Changes in Hong Kong stocks | Cansino Biotech (06185) is now up more than 4% Hib vaccine clinical trial approved, PBPV clinical trial has achieved positive initial results

The Zhitong Finance App learned that Cansino Biotech (06185) is now up more than 4%, with a cumulative increase of more than 18% during the month. As of press release, it rose 4.1% to HK$18.8, with a turnover of HK$17.022,600. According to the news, Cansino Biotech recently announced that the freeze-dried Haemophilus influenzae type b (Hib vaccine) conjugate vaccine (Hib vaccine) developed by the company has been approved by the China National Drug Administration and can carry out related clinical trials. Haemophilus influenzae is a gram-negative bacillus and is one of the most important pathogens of acute lower respiratory infections in children. Cansino Biotech also previously announced the recombinant pneumonia developed by the company

Zhitong FinanceApr 24 23:35 ET

康希諾生物：2023年度報告

Futu NewsApr 24 09:00 ET · Announcements

Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter

Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.

Zhitong FinanceApr 23 01:55 ET

The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year

Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.

金吾財訊Apr 23 01:51 ET

Changes in Hong Kong stocks | Cansino Biotech (06185) once rose nearly 6% and freeze-dried Haemophilus influenzae type b conjugate vaccine was approved for clinical trials

At one point, Cansino Biotech (06185) rose nearly 6%. As of press release, it rose 4.69% to HK$18.32, with a turnover of HK$8.3079 million.

Zhitong FinanceApr 22 21:53 ET

Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine

Cansino Biologics (HKG:6185) received approval from the National Medical Products Administration of China to begin clinical trials for its Haemophilus influenzae Type B (Hib) Conjugate Vaccine, a Mond

MT NewswiresApr 22 08:41 ET